Product
19(T2)28z1xx TRAC T cell
1 clinical trial
6 indications
Indication
B-cell lymphomaIndication
Diffuse Large B-cell LymphomaIndication
Diffuse Large B-Cell LymphomaIndication
Noonan syndromeIndication
High-grade B-cell lymphomaIndication
Mediastinal Large B-cell LymphomaClinical trial
A Phase I Study of T-cell Receptor Alpha Constant (TRAC) Locus Integrated CD19-Targeted 19(T2)28z1xx Chimeric Antigen Receptor (CAR) Modified T Cells in Adult Patients With CD19+ Relapsed or Refractory Large B-Cell LymphomaStatus: Recruiting, Estimated PCD: 2025-02-23